BIB:NSD-ProShares Ultra Nasdaq Biotechnology (USD)

ETF | Trading--Leveraged Equity |

Last Closing

USD 63.755

Change

+0.57 (+0.89)%

Market Cap

USD 0.09B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Trading--Leveraged Equity

Symbol Name Price(Change) Market Cap
TQQQ ProShares UltraPro QQQ

+0.56 (+0.78%)

USD 24.55B
TQQQ ProShares UltraPro QQQ

+0.56 (+0.78%)

USD 24.55B

ETFs Containing BIB

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.75% 25% F 69% C-
Dividend Return 0.80% 25% F 19% F
Total Return 12.56% 25% F 68% D+
Trailing 12 Months  
Capital Gain 36.72% 25% F 79% B-
Dividend Return 1.06% 25% F 15% F
Total Return 37.79% 25% F 78% C+
Trailing 5 Years  
Capital Gain 57.11% 25% F 72% C
Dividend Return 1.27% 25% F 4% F
Total Return 58.38% 25% F 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 3.46% N/A N/A 52% F
Dividend Return 3.52% N/A N/A 49% F
Total Return 0.06% N/A N/A 3% F
Risk Return Profile  
Volatility (Standard Deviation) 36.59% N/A N/A 51% F
Risk Adjusted Return 9.62% N/A N/A 46% F
Market Capitalization 0.09B 25% F 36% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.